NasdaqGS - Delayed Quote • USD
Rallybio Corporation (RLYB)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 7:18 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.37 | -0.35 | -1.41 | -1.25 |
| Low Estimate | -0.46 | -0.48 | -1.77 | -1.77 |
| High Estimate | -0.25 | -0.28 | -0.93 | -0.56 |
| Year Ago EPS | -0.46 | -0.45 | -1.84 | -1.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.51 | -0.45 | -0.47 |
| EPS Actual | -0.46 | -0.45 | -0.5 | -0.47 |
| Difference | 0.02 | 0.06 | -0.05 | 0 |
| Surprise % | 4.20% | 11.80% | -11.10% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.35 | -1.41 | -1.25 |
| 7 Days Ago | -0.37 | -0.35 | -1.41 | -1.25 |
| 30 Days Ago | -0.41 | -0.38 | -1.6 | -1.47 |
| 60 Days Ago | -0.4 | -0.37 | -1.57 | -1.45 |
| 90 Days Ago | -0.43 | -0.41 | -1.68 | -1.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 4 | 2 | 4 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RLYB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 19.60% | -- | -- | 8.30% |
| Next Qtr. | 22.20% | -- | -- | 10.70% |
| Current Year | 23.40% | -- | -- | 4.90% |
| Next Year | 11.30% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.23% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | JP Morgan: Overweight to Neutral | 5/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/19/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/18/2024 |
| Maintains | Wedbush: Outperform to Outperform | 4/11/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/13/2024 |
Related Tickers
TSBX Turnstone Biologics Corp.
2.8000
+5.26%
TYRA Tyra Biosciences, Inc.
19.78
-0.10%
TNYA Tenaya Therapeutics, Inc.
3.6400
-0.82%
GLUE Monte Rosa Therapeutics, Inc.
3.9800
-5.01%
XLO Xilio Therapeutics, Inc.
1.0500
+2.94%
VOR Vor Biopharma Inc.
1.2250
-3.16%
ELYM Eliem Therapeutics, Inc.
8.88
+4.72%
CGEM Cullinan Therapeutics, Inc.
22.40
-0.62%
STTK Shattuck Labs, Inc.
7.02
-3.31%
CMPX Compass Therapeutics, Inc.
1.3100
0.00%